Clearpoint Neuro Slides 2% as Investors Await Key Phase‑II Milestones and Market Turnaround
Clearpoint Neuro (CLPT) sees share prices slide amid market‑wide uncertainty; analysts await key trial results to gauge its neuromodulation future.
2 minutes to read